Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Rumpl3StiltSkinon Feb 23, 2023 4:57pm
178 Views
Post# 35302000

RE:RE:"impressive, paradigm shifting, photodynamic therapy"

RE:RE:"impressive, paradigm shifting, photodynamic therapy"Well Slayer , We've been looking at this for many years now as a pivitol Phase 2. So Maybe Dr. Uddin is thinking a phase 3 will have to happen? I doubt it will take TLT another 3 years to treat ~50-60 more patients at 20 sites? I do think the criteria is still 20-25 CR data to apply for AA and that can happen with merely a FTD.  BTD would just speed the process up. Perhaps Dr. Uddin isn't aware? Anyway FDA has a certain amount of time to respond to any application by TLT. I see no reason why the current data, once tallied, wouldn't suffice towards this BTD/AA application. 

Slayer, I hope Dr. Uddin is just over looking something here. Or maybe you are correct about the ~100/125  patients being the new norm. I still think that would mean we get AA next year. Not 2026.
<< Previous
Bullboard Posts
Next >>